Drug Sequencing Strategies in Metastatic Pancreatic Cancer

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Release Date: April 17, 2017
Expiration Date: April 17, 2018

Expected time to complete this activity as designed: 30 minutes

There are no fees for participating in or receiving credit for this online activity.

Program Overview

The treatment and management of metastatic pancreatic cancer is challenging, in part due to the lack of consensus around a true standard of care. However, the availability of nab-paclitaxel plus gemcitabine in the first-line setting, and nanoliposomal irinotecan plus fluorouracil and leucovorin in the second-line setting creates options for drug sequencing to individualize treatment plans for patients with metastatic disease. In this activity, participants will be provided with an overview of treatment paradigms for first- and second-line metastatic pancreatic cancer, and insight into different drug sequencing strategies tailored to individual patient- and disease-related factors, such as age, comorbidities, performance status, and response/toxicity to prior therapy.

Target Audience

This activity is designed for multidisciplinary health care providers in the community setting, including oncologists, pharmacists, and associated multidisciplinary clinicians who may provide care to patients with pancreatic cancer.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Outline the current treatment paradigms and therapeutic recommendations for patients with metastatic pancreatic cancer in the first- and second-line settings
  • Explain various drug sequencing strategies that may be implemented in practice based upon individual patient- and disease-related factors
  • Describe the future of drug sequencing in metastatic pancreatic cancer through an assessment of novel therapies and drug combinations under investigation in clinical trials

Agenda

Drug Sequencing Strategies in Metastatic Pancreatic Cancer – Bert H. O’Neil, MD

Instructions for Participation and Credit

This activity is eligible for credit through April 17, 2018. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biography

Bert H. O’Neil, MD
Chief Scientific Officer
Hoosier Cancer Research Network
Director, Gastrointestinal Cancer Research Program
IU Simon Cancer Center
Indianapolis, Indiana

Dr. Bert O’Neil received his medical degree from the University of California, Los Angeles, and completed his internal medicine residency and fellowship in hematology/oncology at the University of California, San Francisco. He is the Chief Scientific Officer at the Hoosier Cancer Research Network in Indianapolis, Indiana. He is also the Phase I Clinical Trial Program Director and Director of the Gastrointestinal Cancer Research Program at the IU Simon Cancer Center in Indianapolis.

Dr. O’Neil is a member of the Alliance Gastrointestinal Committee, a Journal of Clinical Oncology editorial board member, and a reviewer for multiple oncology journals. His area of expertise is in gastrointestinal cancers, with a particular concentration on pancreas, colorectal, and hepatocellular (primary liver) carcinomas.

Accreditation

MediCom CME CREDIT
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ACPE CPE CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.5 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-17-139-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosure

Dr. Bert O’Neil has received honoraria as a consultant from Amgen Inc., Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, and Genentech, Inc.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, has no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at lisa@medicaled.com.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Celgene Corporation

©2017 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Partners in Pancreatic Cancer would like to recognize and thank Celgene Corporation
for their educational support of PartnersinPancreaticCancer.com.

©2017 MediCom Worldwide, Inc. All rights reserved